Cargando…
Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study
Background: Type 2 diabetes is related to an increased risk of dementia. Preclinical studies of dipeptidyl peptidase-IV inhibitors (DPP-4i) for dementia have yielded promising results. Therefore, we investigated the risk of dementia in elderly patients with type 2 diabetes on DPP-4is and sulfonylure...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352270/ https://www.ncbi.nlm.nih.gov/pubmed/30597861 http://dx.doi.org/10.3390/jcm8010028 |
_version_ | 1783390796147326976 |
---|---|
author | Kim, Young-Gun Jeon, Ja Young Kim, Hae Jin Kim, Dae Jung Lee, Kwan-Woo Moon, So Young Han, Seung Jin |
author_facet | Kim, Young-Gun Jeon, Ja Young Kim, Hae Jin Kim, Dae Jung Lee, Kwan-Woo Moon, So Young Han, Seung Jin |
author_sort | Kim, Young-Gun |
collection | PubMed |
description | Background: Type 2 diabetes is related to an increased risk of dementia. Preclinical studies of dipeptidyl peptidase-IV inhibitors (DPP-4i) for dementia have yielded promising results. Therefore, we investigated the risk of dementia in elderly patients with type 2 diabetes on DPP-4is and sulfonylureas (SU). Methods: Using a claims database called the Korean National Health Insurance Service Senior cohort, new users of DPP-4is and SUs were matched by 1:1 propensity score matching using 49 confounding variables (7552 new DPP-4is users and 7552 new SU users were matched by 1:1 propensity score matching; average age 75.4; mean follow-up period: 1361.9 days). Survival analysis was performed to estimate the risk of dementia. Results: The risk of all-cause dementia was lower in the DPP-4i group compared to the SU group (hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.56–0.78; p < 0.001). Particularly, DPP-4i use showed a significantly lower risk of Alzheimer’s disease (HR 0.64; 95% CI 0.52–0.79; p < 0.001) and a lower risk, albeit non-significant, of vascular dementia compared to SU use (HR 0.66; 95% CI 0.38–1.14; p = 0.139). Conclusion: Our findings suggest that DPP-4i use decreases the risk of dementia compared to SU use in elderly patients with type 2 diabetes in a real-world clinical setting. |
format | Online Article Text |
id | pubmed-6352270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63522702019-02-01 Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study Kim, Young-Gun Jeon, Ja Young Kim, Hae Jin Kim, Dae Jung Lee, Kwan-Woo Moon, So Young Han, Seung Jin J Clin Med Article Background: Type 2 diabetes is related to an increased risk of dementia. Preclinical studies of dipeptidyl peptidase-IV inhibitors (DPP-4i) for dementia have yielded promising results. Therefore, we investigated the risk of dementia in elderly patients with type 2 diabetes on DPP-4is and sulfonylureas (SU). Methods: Using a claims database called the Korean National Health Insurance Service Senior cohort, new users of DPP-4is and SUs were matched by 1:1 propensity score matching using 49 confounding variables (7552 new DPP-4is users and 7552 new SU users were matched by 1:1 propensity score matching; average age 75.4; mean follow-up period: 1361.9 days). Survival analysis was performed to estimate the risk of dementia. Results: The risk of all-cause dementia was lower in the DPP-4i group compared to the SU group (hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.56–0.78; p < 0.001). Particularly, DPP-4i use showed a significantly lower risk of Alzheimer’s disease (HR 0.64; 95% CI 0.52–0.79; p < 0.001) and a lower risk, albeit non-significant, of vascular dementia compared to SU use (HR 0.66; 95% CI 0.38–1.14; p = 0.139). Conclusion: Our findings suggest that DPP-4i use decreases the risk of dementia compared to SU use in elderly patients with type 2 diabetes in a real-world clinical setting. MDPI 2018-12-28 /pmc/articles/PMC6352270/ /pubmed/30597861 http://dx.doi.org/10.3390/jcm8010028 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Young-Gun Jeon, Ja Young Kim, Hae Jin Kim, Dae Jung Lee, Kwan-Woo Moon, So Young Han, Seung Jin Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study |
title | Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study |
title_full | Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study |
title_fullStr | Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study |
title_full_unstemmed | Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study |
title_short | Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study |
title_sort | risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase iv inhibitors versus sulfonylureas: a real-world population-based cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352270/ https://www.ncbi.nlm.nih.gov/pubmed/30597861 http://dx.doi.org/10.3390/jcm8010028 |
work_keys_str_mv | AT kimyounggun riskofdementiainolderpatientswithtype2diabetesondipeptidylpeptidaseivinhibitorsversussulfonylureasarealworldpopulationbasedcohortstudy AT jeonjayoung riskofdementiainolderpatientswithtype2diabetesondipeptidylpeptidaseivinhibitorsversussulfonylureasarealworldpopulationbasedcohortstudy AT kimhaejin riskofdementiainolderpatientswithtype2diabetesondipeptidylpeptidaseivinhibitorsversussulfonylureasarealworldpopulationbasedcohortstudy AT kimdaejung riskofdementiainolderpatientswithtype2diabetesondipeptidylpeptidaseivinhibitorsversussulfonylureasarealworldpopulationbasedcohortstudy AT leekwanwoo riskofdementiainolderpatientswithtype2diabetesondipeptidylpeptidaseivinhibitorsversussulfonylureasarealworldpopulationbasedcohortstudy AT moonsoyoung riskofdementiainolderpatientswithtype2diabetesondipeptidylpeptidaseivinhibitorsversussulfonylureasarealworldpopulationbasedcohortstudy AT hanseungjin riskofdementiainolderpatientswithtype2diabetesondipeptidylpeptidaseivinhibitorsversussulfonylureasarealworldpopulationbasedcohortstudy |